Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis

BMC Primary Care

Table 1 Characteristics of the included randomized controlled trials and two incompletely reported trials

References	Number of participants	Age (yr)	Setting (country)	Treatment	Comparison	Follow up	Dropouts
de Mey et al. 2008 [15]	92	n.r.*	outpatients (n.r)	Ambroxol 5, 10, 20 mg	Placebo	1 day	11
Schutz et al. 2002^,[14]	215	39,4 ± 15	outpatients (Germany)	Ambroxol 20 mg	Placebo	2 days	19
Fischer et al. 2002 [16]	331	37 ± 13	outpatients (RSA)	Ambroxol 20, 30 mg	Placebo	3 days	48
Fischer et al. 2002 [16]	383	36 ± 12	outpatients (RSA)	Ambroxol 20, 30 mg	Placebo	3 days	58
de Mey et al. 2008 [15]	751	n.r.*	outpatients (n.r.)	Ambroxol 20, 3 mg benzocaine**	Placebo	3 days	27
Registered trials with incompletely reported results
clinicaltrials.gov 2006	221	n.r.	outpatients (RSA)	Ambroxol 20 mg	Placebo	3 days	0
clinicaltrials.gov 2008	259	n.r.	outpatients (China)	Ambroxol 20 mg	Placebo	n.r.	0

n.r. = not reported, RSA = Republic of South Africa, * inclusion age was 16 to 80 years, but average age for those trials was not reported **the outcome of the benzocaine treatment arm is not reported.

ISSN: 2731-4553